117 related articles for article (PubMed ID: 8205750)
21. Substrate turnover during prolonged exercise in man. Splanchnic and leg metabolism of glucose, free fatty acids, and amino acids.
Ahlborg G; Felig P; Hagenfeldt L; Hendler R; Wahren J
J Clin Invest; 1974 Apr; 53(4):1080-90. PubMed ID: 4815076
[TBL] [Abstract][Full Text] [Related]
22. Neuropeptide Y is released together with noradrenaline from the human heart during exercise and hypoxia.
Kaijser L; Pernow J; Berglund B; Lundberg JM
Clin Physiol; 1990 Mar; 10(2):179-88. PubMed ID: 2318028
[TBL] [Abstract][Full Text] [Related]
23. Hepatic glucose production and splanchnic glucose exchange in hyperthyroidism.
Wennlund A; Felig P; Hagenfeldt L; Wahren J
J Clin Endocrinol Metab; 1986 Jan; 62(1):174-80. PubMed ID: 3510000
[TBL] [Abstract][Full Text] [Related]
24. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin.
van den Hoek AM; Voshol PJ; Karnekamp BN; Buijs RM; Romijn JA; Havekes LM; Pijl H
Diabetes; 2004 Oct; 53(10):2529-34. PubMed ID: 15448080
[TBL] [Abstract][Full Text] [Related]
25. Circulating endothelin-1 reduces splanchnic and renal blood flow and splanchnic glucose production in humans.
Ahlborg G; Weitzberg E; Lundberg JM
J Appl Physiol (1985); 1995 Jul; 79(1):141-5. PubMed ID: 7559211
[TBL] [Abstract][Full Text] [Related]
26. Potassium, glucose, insulin interrelationships during adrenaline infusion in normotensive and hypertensive humans.
Gordon RD; Bachmann AW; Ballantine DM; Thompson RE
Clin Exp Pharmacol Physiol; 1991 May; 18(5):291-4. PubMed ID: 2065473
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effect of neuropeptide Y on stimulated renin secretion of awake rats.
Aubert JF; Walker P; Grouzmann E; Nussberger J; Brunner HR; Waeber B
Clin Exp Pharmacol Physiol; 1992 Apr; 19(4):223-8. PubMed ID: 1325309
[TBL] [Abstract][Full Text] [Related]
28. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction.
Moleda L; Trebicka J; Dietrich P; Gäbele E; Hellerbrand C; Straub RH; Sauerbruch T; Schoelmerich J; Wiest R
Gut; 2011 Aug; 60(8):1122-32. PubMed ID: 21317421
[TBL] [Abstract][Full Text] [Related]
29. Effect of adrenaline on glucose kinetics during exercise in adrenalectomised humans.
Howlett K; Galbo H; Lorentsen J; Bergeron R; Zimmerman-Belsing T; Bülow J; Feldt-Rasmussen U; Kjaer M
J Physiol; 1999 Sep; 519 Pt 3(Pt 3):911-21. PubMed ID: 10457100
[TBL] [Abstract][Full Text] [Related]
30. Splanchnic and muscle fructose metabolism during and after exercise.
Ahlborg G; Björkman O
J Appl Physiol (1985); 1990 Oct; 69(4):1244-51. PubMed ID: 2262441
[TBL] [Abstract][Full Text] [Related]
31. Stimulation of the sympathetic perimesenteric arterial nerves releases neuropeptide Y potentiating the vasomotor activity of noradrenaline: involvement of neuropeptide Y-Y1 receptors.
Donoso MV; Brown N; Carrasco C; Cortes V; Fournier A; Huidobro-Toro JP
J Neurochem; 1997 Sep; 69(3):1048-59. PubMed ID: 9282927
[TBL] [Abstract][Full Text] [Related]
32. Influence of neuropeptide Y on regional vascular capacitance in dogs.
Deschamps A; Fournier A; Magder S
Am J Physiol; 1994 Jan; 266(1 Pt 2):H165-70. PubMed ID: 7905715
[TBL] [Abstract][Full Text] [Related]
33. Role of neuropeptide Y in the development of two-kidney, one-clip renovascular hypertension in the rat.
Shin LH; Dovgan PS; Nypaver TJ; Carretero OA; Beierwaltes WH
J Vasc Surg; 2000 Nov; 32(5):1015-21. PubMed ID: 11054234
[TBL] [Abstract][Full Text] [Related]
34. Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock.
Reinelt H; Radermacher P; Kiefer P; Fischer G; Wachter U; Vogt J; Georgieff M
Crit Care Med; 1999 Feb; 27(2):325-31. PubMed ID: 10075057
[TBL] [Abstract][Full Text] [Related]
35. Effects of elevated plasma adrenaline levels on substrate metabolism, effort perception and muscle activation during low-to-moderate intensity exercise.
West SJ; Goedecke JH; van Niekerk L; Collins M; St Clair Gibson A; Macdonald IA; Noakes TD; Lambert EV
Pflugers Arch; 2006 Mar; 451(6):727-37. PubMed ID: 16215769
[TBL] [Abstract][Full Text] [Related]
36. Renal actions of neuropeptide Y in the primate.
Echtenkamp SF; Dandridge PF
Am J Physiol; 1989 Apr; 256(4 Pt 2):F524-31. PubMed ID: 2705532
[TBL] [Abstract][Full Text] [Related]
37. Hormonal and metabolic effects of paraventricular hypothalamic administration of neuropeptide Y during rest and feeding.
van Dijk G; Bottone AE; Strubbe JH; Steffens AB
Brain Res; 1994 Oct; 660(1):96-103. PubMed ID: 7828007
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase inhibition potentiates the renal vascular response to endothelin-1 in humans.
Ahlborg G; Lundberg JM
J Appl Physiol (1985); 1998 Nov; 85(5):1661-6. PubMed ID: 9804567
[TBL] [Abstract][Full Text] [Related]
39. Differential action of hepatic sympathetic neuropeptides: metabolic action of galanin, vascular action of NPY.
Mundinger TO; Taborsky GJ
Am J Physiol Endocrinol Metab; 2000 Mar; 278(3):E390-7. PubMed ID: 10710492
[TBL] [Abstract][Full Text] [Related]
40. The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis.
Wahren J; Eriksson LS
Scand J Gastroenterol Suppl; 1986; 119():103-8. PubMed ID: 2876492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
